Abstract: The invention relates to a substantially laminary manufacture comprising 2 substantially laminary layers in contact, wherein the layers comprise a woven, hydrophilic material.

Abstract: The invention relates to a substantially laminary manufacture comprising 2 substantially laminary layers in contact, wherein the layers comprise a woven, hydrophilic material.

Abstract: The invention provides a manual or automated method for eliminating or minimizing retention time shifts in comprehensive two-dimensional gas chromatography (abbreviated GCxGC). Under nominal identical conditions (identical column-set specifications and GCxGC oven temperature programming), the invention allows one to reproduce the two-dimensional retention times from one column-set to another, from one GCxGC to another or from one column outlet pressure to another. A procedure is described to manually or automatically adjust the head pressure of the primary column and the (effective) secondary column length to compensate for the two-dimensional retention time differences.

Abstract: The present invention relates to granules comprising a ?-lactam antibiotic, wherein CH2S(72h)<50 ?l of H2S gas per kg of ?-lactam antibiotic, wherein CH2S(72h) is the volume of H2S gas above said granules per kg of said ?-lactam antibiotic, when a sample of between 3.5 and 4.5 g of said granules is kept in a closed container having a volume of 20 ml at a temperature of 22° C. during 72 hours at atmospheric pressure (1 bar). The invention also relates to a process for the preparation of granules comprising a ?-lactam antibiotic, said process comprising feeding said ?-lactam antibiotic to a roller compactor to form compacts, size reducing, e.g. milling the compacts to produce granules, wherein the temperature of the ?-lactam antibiotic that is fed to the roller compactor is sufficiently low that CH2S(72h)<50 ?l of H2S gas per kg of ?-lactam antibiotic, wherein CH2S(72h) is the volume of H2S gas above said granules per kg of said ?-lactam antibiotic, when a sample of between 3.5 and 4.

Abstract: The invention relates to isolated mutants of enzymes from the group of 2-deoxy-D-ribose 5-phosphate aldolase wild-type enzymes having a productivity factor (as determined by a specific test) which is at least 10% higher than the productivity factor for the corresponding wild-type enzyme from which it is a mutant. The mutants have at least one amino acid substitution at one or more of the positions corresponding to K13, T19, Y49, N80, D84, A93, E127, A128, K146, K160, I166, A174, M185, K196, F200, and S239 in Escherichia coli K12 (EC 4.1.2.4) wild-type enzyme sequence, and/or a deletion of at least one amino acid at the positions corresponding to S258 and Y259 therein, optionally combined with, specific, C-terminal extension and/or N terminal extension.